Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Tumor, Solid · Pancreatic Cancer · Melanoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Contact: Study coordinator (Melissa Flores) · melissa_flores@med.unc.edu
Contact: Study coordinator (Stergios Moschos) · (866) 869-1856
Contact: Principal Investigator (Stergios Moschos, MD)

Study leads

Stergios Moschos, MD
Principal Investigator
University of North Carolina, Chapel Hill

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Cancer · Tumor, Solid · Malignant Neoplasm

Abroad (travel likely)RecruitingPHASE1, PHASE2

Austin, United States · Irving, United States

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE1

North Melbourne, Australia

Pan-tumor MRD Study

Muscle Invasive Bladder Urothelial Carcinoma · Esophageal Cancer · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Abroad (travel likely)Recruiting

San Diego, United States · Maumee, United States

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

PIK3CA Mutation · Solid Tumor, Adult · HER2-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Tucson, United States · San Diego, United States